Swedish Research Council

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

Retrieved on: 
Mardi, novembre 14, 2023
Swedish Research Council, Leukotriene, Safety, Nations in Swedish universities, Immunomodulation, Disease, PD, Cysteinyl leukotriene receptor 1, Tablet, Patient, Karolinska University Hospital, MPA, Alzheimer's disease, United, IGX, MD, SCI, Trial of the century, Neurodegenerative disease, Doctor of Philosophy, L-DOPA, TSX, Medical Products Agency (Sweden), Pharmaceutical industry

The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa.

Key Points: 
  • The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa.
  • Early results have indicated its potential usefulness for the treatment of various neurodegenerative disorders like PD and Alzheimer’s Disease.
  • The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period.
  • 3 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Retrieved on: 
Mardi, juillet 25, 2023
Intellectual property, PD, Karolinska University Hospital, Neuroscience, Swedish Research Council, Doctor of Philosophy, Trial of the century, Tablet, MD, TSX, Pharmaceutical industry, Study

The Study will be conducted at the Karolinska University Hospital under IntelGenx’s previously announced research collaboration with Per Svenningsson, MD, PhD, who will serve as the Study’s Principal Investigator.

Key Points: 
  • The Study will be conducted at the Karolinska University Hospital under IntelGenx’s previously announced research collaboration with Per Svenningsson, MD, PhD, who will serve as the Study’s Principal Investigator.
  • Dr. Svenningsson – a Professor of Clinical Neuroscience who investigates the pathogenic mechanisms of PD – previously conducted a clinical study utilizing the tablet form of Montelukast for the treatment of PD, where 2 tablets of 10 mg Montelukast were administered twice daily, for a total daily dose of 40 mg.
    “Prof.
  • $2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.
  • Upon completion of the Study, IntelGenx will have the option to acquire the developed intellectual property rights and study data for a predetermined low five-digit amount and use the findings to further develop its Montelukast VersaFilm® program for PD treatment.

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Retrieved on: 
Jeudi, février 9, 2023
Disease, Movement disorders, Neurodegeneration, Parkinson, Cysteinyl leukotriene receptor 1, Karolinska Institute, Immunomodulation, Trial of the century, Principal, Clinical neuroscience, Per Svenningsson, TSX, Swedish Research Council, Government budget balance, Parkinson's disease, Intellectual property, Lewy body, Clinical trial, Alzheimer's disease, Leukotriene, SCI, Research, Doctor of Philosophy, Pharmaceutical industry, MD, PD, Study

$2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.

Key Points: 
  • $2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.
  • IntelGenx will supply Dr. Svenningsson with both active and placebo films to be used in the 18-month treatment regimen for study participants.
  • Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
  • 2 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

Mats Danielsson receives the Hans Wigzell Research Foundation's science prize amounting to SEK 925,000.

Retrieved on: 
Jeudi, décembre 8, 2022
Rolf Schock Prizes, Danielsson, Physics, Degenerative disease, Swedish Medical Society, Science, KI, KTH Royal Institute of Technology, Diagnosis, Swedish Foundation for Strategic Research, Karolinska Institute, Department of Engineering Science, University of Oxford, IVA, Cancer, Royal Swedish Academy of Sciences, Research, Infectious Diseases Institute, Nobel Committee, CERN, Silicon, Swedish Research Council, Royal Academy of Arts, Value Partners (asset management), Erna, Education, Research Foundation – Flanders (FWO), Organization, Electronics, SEK, Risk, Pharmaceutical industry, Medical imaging, EU

STOCKHOLM, Dec. 8, 2022 /PRNewswire/ -- The Hans Wigzell's Research Foundation awards its annual scientific prize, to Professor Mats Danielsson at the KTH Royal Institute of Technology in Stockholm.

Key Points: 
  • STOCKHOLM, Dec. 8, 2022 /PRNewswire/ -- The Hans Wigzell's Research Foundation awards its annual scientific prize, to Professor Mats Danielsson at the KTH Royal Institute of Technology in Stockholm.
  • Professor Mats Danielsson receives the prize of SEK 925,000 for his research around medical imaging technology, a technology that can enable earlier diagnosis of cancer and cardiovascular diseases.
  • Mats Danielsson leads a research group at KTH Royal Institute of Technology in physics of medical imaging.
  • Mats Danielsson has a background as a particle physicist and wrote his dissertation on a thesis based on research at CERN.

mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA

Retrieved on: 
Mardi, août 23, 2022
COO, Partnership, COVID-19, CEO, Thermo Fisher Scientific, Therapy, Swedish Research Council, LSP, Coronavirus, Distinguishing, Novalis, CGMP, Network as a service, Bayer, GLOBE, List of life sciences, Karolinska Institute, Leadership, Company, Marijn Dekkers, LNP, Mindful Scientific Inc., Knowledge, RNA transfection, Moderna, Marijn, Industry, PMV, Management, Vaccine

The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, a world-renowned expert in mRNA technology and its therapeutic applications.

Key Points: 
  • The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, a world-renowned expert in mRNA technology and its therapeutic applications.
  • Existing investors, including LSP (now EQT Life Sciences), PMV, Grand Pharma, Fund+, Omega Fund, and others, also participated in the financing.
  • In addition, eTheRNA announced the departure of its CEO, Steven Powell, and the appointment of current COO, Bernard Sagaert, as interim-CEO.
  • "Similarly, I am delighted to welcome Marijn and Kenneth, both of whom bring extraordinary skills to the board of eTheRNA.

FUNET and SUNET transport 400Gbit/s over record 10,000km distance with ADVA FSP 3000 TeraFlex™

Retrieved on: 
Jeudi, février 17, 2022
Software, Research, Mobile, Wireless, Networks, Professional Services, Data Management, Technology, University, Education, Other Professional Services, Science, Finance, ICT, Information technology, Record, Humphrey School of Public Affairs, 2011 Inter-Continental Hotel Kabul attack, Education, Solution, R, Swedish Research Council, Regeneration, Technology, CSC, OSNR, Nations in Finnish universities, Culture, FSE, ADV, SUNET, Software, FUNET, Multimedia, Research, Industry, Organization, Mobile phone, Rail transport, Science

Using both FUNET and SUNET, the demo harnessed the ADVA FSP 3000 TeraFlex CoreChannel to transmit services at unprecedented line speeds for a live ultra-long-haul network.

Key Points: 
  • Using both FUNET and SUNET, the demo harnessed the ADVA FSP 3000 TeraFlex CoreChannel to transmit services at unprecedented line speeds for a live ultra-long-haul network.
  • (Graphic: Business Wire)
    Our multi-domain field trial with the ADVA FSP 3000 TeraFlex CoreChannel terminal evaluated flexibility and the terminals capabilities to adapt to use cases where ultra-long-haul 400GbE services are needed.
  • We have already built multiple programmable cross-border interconnection links between the FUNET and SUNET ADVA open line systems to exchange spectrum transparently.
  • It was built on ADVA FSP 3000 optical transport technology, which provides a truly open line system fully ready for open spectrum services.

BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board

Retrieved on: 
Mercredi, janvier 26, 2022
NIAAA, CEO, Swedish Research Council, Lists of diseases, Genta (company), COVID-19, Review, Psychiatry, Social, Research, Transcranial magnetic stimulation, Addiction, Tic disorder, Private Securities Litigation Reform Act, Health, U.S. Securities and Exchange Commission, Technology, TMS, NASDAQ, National, Legislation, Knowledge, Anxiety, Center, Uncertainty, Deep, National Institute, Company, Insurance, Annual report, Â, Translation, Brainsway, Patient, Gene expression, Awareness, News, TASE, National Institute on Alcohol Abuse and Alcoholism, NIH, GLOBE, FDA, Failure, Pharmaceutical industry, Medicare, Alcoholism

and JERUSALEM, Jan. 26, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced the addition of Professor Markus Heilig, M.D., Ph.D., to BrainsWays scientific advisory board.

Key Points: 
  • and JERUSALEM, Jan. 26, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced the addition of Professor Markus Heilig, M.D., Ph.D., to BrainsWays scientific advisory board.
  • It is my distinct pleasure to welcome Professor Heilig to our scientific advisory board, said Christopher von Jako, Ph.D., President and CEO of BrainsWay.
  • As a luminary in the field, Professor Heilig will serve a significant role in shaping our future research and clinical strategies.
  • BrainsWay continues to demonstrate their commitment to advancing the field of neuroscience and brain stimulation, and I am honored to join my peers and colleagues as a member of the Companys scientific advisory board, said Professor Heilig.